AI Biosecurity, DNA-Synthesis Screening Fundraising: Ginkgo

How Ginkgo Bioworks Concentric, Karius, Delfi Diagnostics, Ozette, Kernel Biosciences, Aanika Biosciences, IBBIS (Common Mechanism), Twist Bioscience.

Raising Capital for AI-Native Biosecurity, Pandemic Early-Warning, Metagenomic Pathogen Surveillance, Wastewater Epidemiology, DNA-Synthesis Screening, Biothreat Detection & Medical Countermeasure MCM Startups

AI-native biosecurity, pandemic-early-warning, metagenomic-pathogen-surveillance, wastewater-based-epidemiology-WBE, airborne-pathogen-detection, syndromic-surveillance, clinical-metagenomics, mNGS-metagenomic-next-generation-sequencing, Nanopore-Oxford-Nanopore-MinION-PromethION, Illumina-NextSeq-NovaSeq, Element Biosciences Aviti, Ultima Genomics UG-100, PacBio-Revio-HiFi, Singular Genomics G4X, Complete Genomics-MGI, BGI, qPCR, LAMP-Loop-mediated-Isothermal-Amplification, CRISPR-Cas12-Cas13-SHERLOCK-DETECTR, antigen-lateral-flow, DNA-synthesis-screening-Common-Mechanism-IBBIS, IGSC-International-Gene-Synthesis-Consortium, HHS-OSTP-DNA-synthesis-screening-framework-Apr-2024, EO-14110-Biden-AI-executive-order-then-Trump-Jan-2025-rescission-then-EO-14179, Section-4.4-nucleic-acid-synthesis-screening, BWC-Biological-Weapons-Convention, Australia-Group, BSL-3-BSL-4, Select-Agent-CDC-USDA-APHIS, FSAP-Federal-Select-Agent-Program, DURC-Dual-Use-Research-of-Concern, P3CO-Potential-Pandemic-Pathogen-Care-Oversight, PREPP-Pandemic-Rapid-Early-Warning-Program, BARDA-Biomedical-Advanced-Research-Development-Authority, ASPR-Administration-for-Strategic-Preparedness-and-Response, CDC-Center-for-Forecasting-Outbreak-Analytics-CFA, NIH-NIAID, DARPA-Preemptive-Expression-of-Protective-Alleles-PREPARE, IARPA-Fun-GCAT, Bill-Melinda-Gates-Foundation, Wellcome-Leap, Open-Philanthropy, Longview-Philanthropy, Effective-Ventures, Nuclear-Threat-Initiative-NTI, Council-on-Strategic-Risks-CSR, Johns-Hopkins-Center-for-Health-Security is the most under-funded, highest-stakes, national-security-critical AI-plus-bio category for 2026 — validated by COVID-19-SARS-CoV-2-2020-2023, mpox-2022, H5N1-avian-influenza-dairy-cattle-2024-2025, Marburg-Rwanda-2024, Ebola-Uganda-2025, Nipah-Kerala-2024, Oropouche-2024, Rift-Valley-Fever, Crimean-Congo-Hemorrhagic-Fever, Lassa, Chikungunya, Dengue-Puerto-Rico-2024, WHO-Disease-X, WHO-Pathogens-of-Pandemic-Potential-2024-update, CEPI-Coalition-for-Epidemic-Preparedness-Innovations-100-Days-Mission, BARDA Project-NextGen $5B, ARPA-H, NIAID-CIVIC, NIAID-CREID, CDC-CFA-Center-for-Forecasting-Outbreak-Analytics, GISAID, GISRS, WHO-BioHub, Global-Virome-Project, PREDICT-USAID-Ended, DEEP-VZN, Global-Immunological-Observatory GIO, Nucleic-Acid-Observatory-NAO-SecureBio-MIT, Founders-Pledge, Long-Term-Future-Fund, Open-Philanthropy-Biosecurity-Program, AI-x-Bio-risk-Anthropic-OpenAI-DeepMind-Model-Cards, RAND-report-on-LLM-bioweapon-uplift, Frontier-Model-Forum, NIST-AISI-AI-Safety-Institute, UK-AISI, AISIC-AI-Safety-Institute-Consortium, Bletchley-Seoul-Paris-AI-Safety-Summits, International-AI-Safety-Report-Bengio validated AI, LLM-bio-uplift-risk, biosecurity, pathogen-surveillance, DNA-synthesis-screening, wastewater-metagenomics as the top-3 national-security-and-catastrophic-risk category for the 2026-2030 window. Ginkgo Bioworks $NYSE:DNA, Concentric-by-Ginkgo pathogen-surveillance, Boston Logan, JFK, LAX, Miami, O'Hare, Dulles, LaGuardia, IAD, Newark, SEA, SFO, BWI, MSP, PHX, Denver, Charlotte, PHL, BOS-airport-passenger-metagenomic-surveillance, CDC-Traveler-Genomic-Surveillance-TGS-program, Concentric-wastewater-metagenomics, Concentric-Aviation, Concentric-Schools, $2B+ US-government-contract-portfolio, Karius $500M+ raised Khosla-General Catalyst-Lightspeed, plasma-microbial-cell-free-DNA-mcfDNA, Karius-Test, 1000-plus-pathogen-detection, Stanford-spinout, immunocompromised-clinical-diagnostics, $500M+ TAM, Delfi Diagnostics $225M+ B Foresite-Menlo Ventures, fragmentomics-cfDNA, FirstLook-Lung, cell-free-DNA, Johns-Hopkins-spinout, Ozette Technologies $30M+ A Madrona-Bain Capital Ventures, high-dimensional-immunology, spectral-flow, immune-repertoire, Karius-adjacent, Kernel Biosciences $30M+ A Alix-Bio, rapid-pathogen-detection, hospital-acquired-infection-HAI, AMR-antimicrobial-resistance, Aanika Biosciences $30M+ A, biological-barcodes, food-safety, supply-chain-traceability, biothreat-attribution, IBBIS International Biosecurity and Biosafety Initiative for Science, Common Mechanism DNA-synthesis-screening open-source, NTI-founded, Open-Philanthropy-funded, Wellcome-funded, IGSC-International-Gene-Synthesis-Consortium standard-setting, SecureBio-MIT-Kevin-Esvelt Nucleic-Acid-Observatory-NAO, wastewater-metagenomics, pandemic-early-warning, Open-Philanthropy-funded, Longview-funded, MetaBiota, BlueDot-Toronto epidemic-intelligence, NLP, syndromic-surveillance, PredictHQ-adjacent, BioBot Analytics $50M+ B, wastewater-based-epidemiology, CDC-partnership, COVID-mpox-polio-H5N1, 100+ US-cities, Verily-Alphabet, Google-Health biosurveillance-adjacent, Twist Bioscience $NASDAQ:TWST $1B+ market-cap, silicon-based-oligo-synthesis, gene-synthesis, IGSC-founder, DNA-synthesis-screening-leader, Ansa Biotechnologies $68M+ B Northpond-8VC, enzymatic-DNA-synthesis, TdT-Terminal-deoxynucleotidyl-Transferase-based, long-oligos, Elegen $46M+ B Wing-Piva-Menlo, long-DNA-fragment-synthesis, ENFINIA-Elegen-Enterprise, 20kb+, DNA Script $200M+ raised, enzymatic-DNA-synthesis, SYNTAX, benchtop, LG-Chem-JV, Molecular Assemblies $34M+ B Codexis-Northpond, enzymatic-DNA-synthesis, FullyEnzymatic-DNA-Synthesis-FES, Nuclera $75M+ B eDNA-Direct, benchtop-protein-synthesis, eProtein-Discovery, Nuclera-Cambridge-UK, Kernel-DX, Talus Biosciences, BillionToOne cfDNA-adjacent.

Why 2026 is different

Four unlocks: (1) COVID-19, mpox-2022, H5N1-avian-influenza-dairy-cattle-2024-2025, Marburg-Rwanda-2024, Ebola-Uganda-2025, Nipah-Kerala-2024, Oropouche-2024, Dengue-Puerto-Rico-2024, WHO-Disease-X, WHO-Pathogens-of-Pandemic-Potential-2024-update, CEPI-100-Days-Mission, BARDA Project-NextGen $5B, ARPA-H, NIAID-CIVIC, CDC-CFA, GISAID, Nucleic-Acid-Observatory-NAO-SecureBio-MIT validated AI, biosecurity, pathogen-surveillance, DNA-synthesis-screening, wastewater-metagenomics as the top-3 national-security-and-catastrophic-risk category for the 2026-2030 window. (2) RAND-report-on-LLM-bioweapon-uplift, Anthropic-RSP-ASL-3-CBRN, OpenAI-Preparedness-CBRN-Medium-High, DeepMind-Frontier-Safety-CBRN, Meta-Frontier-AI-Framework, Frontier-Model-Forum, NIST-AISI, UK-AISI, AISIC, Bletchley-Seoul-Paris-AI-Safety-Summits, International-AI-Safety-Report-Bengio, Section-4.4-EO-14110-then-EO-14179-Trump-Jan-2025, HHS-OSTP-DNA-synthesis-screening-framework-Apr-2024, IBBIS-Common-Mechanism-open-source-2024-release, IGSC-International-Gene-Synthesis-Consortium proved AI-x-bio-uplift-risk, DNA-synthesis-screening as the enforceable, policy-anchored, government-funded category. (3) Ginkgo Concentric $2B+ US-government-contract-portfolio, BioBot Analytics CDC-partnership, WastewaterSCAN Stanford-Emory, SecureBio-NAO, Karius $500M+ raised, Delfi $225M+ B, Ozette, Kernel, Aanika, Ansa, Elegen, DNA Script, Molecular Assemblies, Nuclera proved biosecurity, pathogen-surveillance, DNA-synthesis-screening, enzymatic-DNA-synthesis as investable, scaled, BARDA-ASPR-CDC-NIH-DARPA-underwritten category. (4) BARDA-Project-NextGen $5B, ARPA-H $2.5B, BARDA base $1B+, NIH-NIAID, DARPA-PREPARE, IARPA-Fun-GCAT, DoD-DTRA, DHS-CBRND, CDC-CFA, ASPR, CEPI-100-Days-Mission, Open-Philanthropy-Biosecurity, Longview, Effective-Ventures, Wellcome-Leap, Gates, CZI created the largest non-dilutive, philanthropic, government-underwritten capital-stack for biosecurity since the 2001-Amerithrax-Anthrax-response, Project-BioShield-2004.

Realistic capital stack

Seed $3-15M for lab, assay-development, first-BARDA-CDC-DARPA-BAA-response, first-CLIA-LDT (SecureBio-NAO Open-Philanthropy, Longview, Aanika, Kernel Biosciences $30M A Alix-Bio, Ozette early). Series A/B $30-500M for first-BARDA, ASPR, CDC, first-FDA-EUA, first-hospital-clinical-launch (Karius $500M+ Khosla-General Catalyst-Lightspeed, Delfi $225M+ B Foresite-Menlo, Ansa $68M+ B Northpond-8VC, Elegen $46M+ B Wing-Piva-Menlo, BioBot Analytics $50M+ B, DNA Script $200M+, Molecular Assemblies $34M+ B Codexis-Northpond, Nuclera $75M+ B). Growth, strategic, IPO $200M-$10B+ for platform, multi-product, hyperscaler, government (Ginkgo Bioworks $NYSE:DNA $2B+ market-cap, Concentric-by-Ginkgo $2B+ US-government-contract-portfolio, Twist Bioscience $NASDAQ:TWST $1B+ market-cap, Illumina $NASDAQ:ILMN $20B+, Danaher-IDT $NYSE:DHR $180B+, Thermo Fisher $NYSE:TMO $200B+, Roche $SWX:ROG $250B+, Roche Sequencing, Element Biosciences private, $500M+ raised, Ultima Genomics private, $600M+ raised, Andreessen-Khosla-Founders Fund-D1, PacBio $NASDAQ:PACB $2B+, Oxford Nanopore $LSE:ONT $2B+ market-cap, GenScript $HK:1548 $1B+ market-cap, Eurofins Scientific $EPA:ERF $10B+ market-cap public-comps). Non-dilutive material — BARDA Project-NextGen $5B, BARDA base $1B+, ARPA-H $2.5B, NIH-NIAID, DARPA-PREPARE, IARPA-Fun-GCAT, DoD-DTRA-Defense-Threat-Reduction-Agency, DHS-CBRND, CDC-CFA-Center-for-Forecasting-Outbreak-Analytics, ASPR, FDA-EUA, CLIA-LDT, WHO-EUL, CEPI-100-Days-Mission, Open-Philanthropy-Biosecurity-Program, Longview-Philanthropy, Effective-Ventures, Founders-Pledge, Long-Term-Future-Fund, Survival-and-Flourishing-Fund, Emergent-Ventures, Schmidt-Futures, Wellcome-Leap, Wellcome-Trust, Bill-Melinda-Gates-Foundation, Chan-Zuckerberg-Initiative-CZI, Rockefeller-Foundation, PATH, DNDi, GAVI, UNICEF non-dilutive-government, philanthropic, $200M-$2B+ ceiling.

Common failure modes

Overclaiming time-to-detection, pathogens-covered, limit-of-detection, government-contract, Common-Mechanism-adoption without third-party-audited, BARDA, ASPR, CDC-CFA, NIH-NIAID, DARPA, FDA-EUA, CLIA-LDT, CAP, WHO-EUL, peer-reviewed, Nature-Medicine-NEJM-Lancet-Cell-Science-published record — post-Ginkgo Concentric, BioBot, WastewaterSCAN, Karius, Delfi, Ozette, Kernel, Aanika, SecureBio-NAO, IBBIS-Common-Mechanism, IGSC, Twist, IDT-Danaher, GenScript, Ansa, Elegen, DNA Script, Molecular Assemblies, Nuclera credible-scale bar, operators without a signed, published, third-party-validated, first-BARDA-CDC-CEPI-BAA, first-FDA-EUA, first-CLIA-LDT, first-peer-reviewed-publication record get flagged by ARCH, Flagship, a16z-Bio, Lux, General Catalyst, Khosla, Lightspeed, Foresite, Menlo, Alix, Madrona, Bain Capital Ventures, Northpond, Piva, Wing, 8VC, Open-Philanthropy, Longview, Effective-Ventures, Wellcome-Leap, Gates, CZI diligence within 12-18 months. Underestimating BSL-3-BSL-4, FSAP-Federal-Select-Agent-Program, Select-Agent-CDC-USDA-APHIS, DURC-Dual-Use-Research-of-Concern, P3CO-Potential-Pandemic-Pathogen-Care-Oversight, NSABB, BWC-Biological-Weapons-Convention, Australia-Group, Wassenaar, EAR, ITAR, OFAC, Section-1758-NDAA-FY2024, Section-889, Section-5949, FEOC, Section-30D, BIS, DDTC, CFIUS, AI-x-bio-uplift-Anthropic-RSP-ASL-3-CBRN, OpenAI-Preparedness-CBRN, DeepMind-Frontier-Safety-CBRN, Meta-Frontier-AI-Framework, Frontier-Model-Forum, NIST-AISI, UK-AISI, AISIC, International-AI-Safety-Report-Bengio, EO-14179-Trump-Jan-2025, Section-4.4-nucleic-acid, HHS-OSTP-Apr-2024, IBBIS-Common-Mechanism-open-source, IGSC regulatory-and-standards. Ignoring FDA-LDT-Final-Rule-Apr-2024, CLIA-Waived-Moderate-High, CAP, 510(k), PMA, de-novo, EUA, WHO-EUL, CE-IVDR, Health-Canada, PMDA-Japan, NMPA-China, ANVISA-Brazil, TGA-Australia, CDSCO-India, BMBL-6th-Edition, ABSA, ASBIC, WHO-Disease-X, WHO-Pathogens-of-Pandemic-Potential, CEPI-100-Days-Mission compliance.

Frequently asked questions

Is there room for another biosecurity, pathogen-surveillance, DNA-synthesis-screening, wastewater-metagenomics, biothreat-detection startup vs. Ginkgo Concentric, Karius, Delfi, Ozette, Kernel, BioBot, SecureBio, IBBIS, Twist, IDT, GenScript, Ansa, Elegen, DNA Script, Molecular Assemblies, Nuclera, Sherlock, Mammoth?
Yes, at the sample-matrix, pathogen-class, detection-modality, geography, downstream-workflow where incumbents don't have depth. Defensible wedges are (a) sample-matrix (blood-plasma-cfDNA Karius-Delfi, respiratory-swab-BAL Sherlock-Mammoth-Visby, wastewater-sludge BioBot-WastewaterSCAN-Ginkgo Concentric-Ceres-Nanotrap, air-indoor-HVAC Poppy-Kanaria, food-agricultural-supply-chain Aanika, environmental-soil-water-Global-Virome-Project-DEEP-VZN, wearable-sweat-skin-Kinsa-Whoop-Oura-Apple-WVU-Rockefeller-Neuroscience), (b) pathogen-class (viral-RNA-DNA, SARS-CoV-2, mpox, H5N1, polio, RSV, flu, Marburg, Ebola, Nipah, Lassa, Rift-Valley, CCHF, Oropouche, Dengue, Chikungunya, Zika, WHO-Disease-X, CEPI-100-Days-Mission-priority, bacterial, AMR-antimicrobial-resistance, carbapenem-resistant-Enterobacterales-CRE, MRSA, VRE, C-diff, M-tuberculosis, Y-pestis, B-anthracis, F-tularensis, Y-enterocolitica, Salmonella, fungal, Candida-auris, Aspergillus, Cryptococcus, Coccidioides, prion, parasitic, toxin, ricin, botulinum, engineered, synthetic-biology, de-novo, gain-of-function, chimeric), (c) detection-modality (qPCR, LAMP, isothermal, CRISPR-Cas12-Cas13-SHERLOCK-DETECTR, antigen-lateral-flow-LFA, immunoassay, ELISA, protein-mass-spec, mNGS-metagenomic-Nanopore-Illumina-Element-Ultima-PacBio-Singular-Complete, biosensor, electrochemical, optical, surface-plasmon-resonance, AI-vision-microscopy, wearable-biosensor), (d) geography, regulatory (US-BARDA-ASPR-CDC-CFA-NIH-NIAID-DARPA-IARPA-DoD-DTRA-DHS-CBRND-FDA-EUA-CLIA-CAP-LDT-IVD-510k-PMA-de-novo, EU-CEPI-ECDC-EMA-CE-IVDR-Health-Canada, Japan-PMDA, Korea-MFDS, India-CDSCO, Brazil-ANVISA, Australia-TGA, China-NMPA, Africa-CDC, Southeast-Asia-WHO-EUL-CEPI-100-Days, LMIC-low-and-middle-income, WHO-EUL, CEPI, PATH, DNDi, GAVI, UNICEF, Global-Fund-adjacent), (e) downstream-workflow (surveillance-only, Ginkgo Concentric, BioBot, clinical-diagnostic, Karius, Delfi, Sherlock, Mammoth, Visby, therapeutic-drug-discovery-integrated, Moderna, Pfizer-BioNTech, Vir, Regeneron, Adagio-Invivyd, Ology, DNA-synthesis-screening, Twist, IDT, GenScript, Ansa, Elegen, DNA Script, Molecular Assemblies, Nuclera, Camena, IBBIS-Common-Mechanism).
Realistic exit?
Strategic acquisition, IPO, government-underwritten dominates: Illumina-Grail $8B 2020-then-divested-2024, Danaher-IDT-Integrated-DNA-Technologies $2B 2018, Thermo Fisher-Life-Technologies $13.6B 2013, Thermo Fisher-Qiagen-attempted-terminated-2020, Roche-Foundation-Medicine $2.4B 2018, Roche-Genia $350M 2014, Roche-Kapa-Biosystems, Bio-Rad-QuantaLife $162M 2011, Bio-Techne-Lunaphore, Bio-Techne-Namocell, Bio-Techne-Asuragen $215M 2021, Bio-Techne-Exosome-Diagnostics $250M 2018, PerkinElmer-BioLegend $5.3B 2021, Danaher-Aldevron $9.6B 2021, Danaher-Beckman-Coulter $6.8B 2011, Danaher-Cepheid $4B 2016, Danaher-Pall $13.8B 2015, Danaher-Cytiva-GE-Biopharma $21B 2020, Sanofi-Bioverativ $11.6B 2018, Sanofi-Ablynx $4.8B 2018, Sanofi-Provention-Bio $2.9B 2023, Amgen-Horizon-Therapeutics $27.8B 2023, Pfizer-Seagen $43B 2023, Merck-Prometheus $10.8B 2023, Merck-Acceleron $11.5B 2021, AstraZeneca-Alexion $39B 2021, Novartis-The-Medicines-Company $9.7B 2020, BMS-Celgene $74B 2019, BMS-MyoKardia $13.1B 2020, BMS-Turning-Point $4.1B 2022, BMS-RayzeBio $4.1B 2024, BMS-Karuna $14B 2024, BMS-Mirati $4.8B 2023, Ipsen-Epizyme $247M 2022, AbbVie-Cerevel $8.7B 2024, AbbVie-ImmunoGen $10.1B 2024, AbbVie-Landos $137M 2024, Boehringer-Trutino, GSK-Aiolos, GSK-Bellus-Health $2B 2023, GSK-Sierra-Oncology $1.9B 2022, J&J-Ambrx $2B 2024, J&J-Intra-Cellular-Therapies $14.6B 2025, Danaher-Abcam $5.7B 2023, Danaher-Chase-Sun, Danaher-Genedata, Danaher-Leica-Microsystems, Danaher-SCIEX-adjacent strategic-pharma-and-tools. IPO reserved for platform-plus-multi-product leaders — Ginkgo Bioworks $NYSE:DNA, Twist Bioscience $NASDAQ:TWST, Illumina $NASDAQ:ILMN, Danaher $NYSE:DHR, Thermo Fisher $NYSE:TMO, Roche $SWX:ROG, PacBio $NASDAQ:PACB, Oxford Nanopore $LSE:ONT, GenScript $HK:1548, Eurofins Scientific $EPA:ERF, Moderna $NASDAQ:MRNA, Vir Biotechnology $NASDAQ:VIR, Novavax $NASDAQ:NVAX, Adagio-Invivyd $NASDAQ:IVVD, Regeneron $NASDAQ:REGN, Element Biosciences private-$500M+-raised, Ultima Genomics private-$600M+-raised, Singular Genomics $NASDAQ:OMIC, Complete Genomics-MGI-BGI $SHE:300676 public-comps. Strategic acquisition — Illumina, Danaher, Thermo Fisher, Roche, Bio-Rad, PerkinElmer, Agilent, Waters, Bruker, Mettler-Toledo, Sartorius, Merck-KGaA-MilliporeSigma, Cytiva-GE-Biopharma, Lonza, Catalent, Charles River Laboratories, Labcorp, Quest Diagnostics, IQVIA, ICON plc, Syneos-Fortrea, Parexel, Medpace, PPD-Thermo, PRA-ICON, Certara, Veeva, BenchSci, Owkin, Aetion, Komodo Health, Truveta, Datavant, Verantos, Flatiron-Roche, Foundation-Medicine-Roche, Guardant, Natera, Exact Sciences, Grail-Illumina-divested, Freenome, Delfi-adj, Karius-adj, Ginkgo-Concentric-adj strategic-diagnostics-and-tools. Government, philanthropic, non-M&A — BARDA Project-NextGen $5B, BARDA base $1B+, ARPA-H $2.5B, NIH-NIAID, DARPA-PREPARE, IARPA-Fun-GCAT, DoD-DTRA, DHS-CBRND, CDC-CFA, ASPR, CEPI-100-Days-Mission, Open-Philanthropy-Biosecurity-Program, Longview-Philanthropy, Effective-Ventures, Wellcome-Leap, Wellcome-Trust, Bill-Melinda-Gates-Foundation, CZI, Rockefeller-Foundation, PATH, DNDi, GAVI, UNICEF long-duration, non-dilutive, $200M-$2B+ ceiling.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database